Senegal

in page functions
[French]
Senegal
Total population (2016) 15,589,480
Birth cohort (2016) 574,397
Surviving Infants (surviving to 1 year per year, 2016) 553,357
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 42/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 47/1000
World Bank Index, IDA (2012) 3.68
Co-financing status (2016) Preparatory transition
No. of districts/territories (2015) 76

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Senegal

Type of support

Approvals

2001-2021 (US$)
(20 Dec 2016)

Commitments

2001-2021 (US$)
(20 Dec 2016)

Disbursements

2000-2016 (US$)
(20 Dec 2016)

% Disbursed

(20 Dec 2016)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $114,228,560 $129,155,007 $109,028,237
Cash Support (CASHSUPP) $145,000 $170,000 $145,000 100%
Health system strengthening (HSS 1) $3,585,500 $3,585,500 $3,585,500 100%
Health system strengthening (HSS 2) $8,319,422 $13,439,369 $4,504,699 54%
HepB mono (NVS) $588,743 $588,743 $588,743 100%
HPV Demo (NVS) $202,609 $202,609 $204,576 101%
Immunisation services support (ISS) $2,605,740 $2,605,740 $2,605,740 100%
Injection Safety Devices (NVS) $107,000 $298,000
Injection safety support (INS) $619,474 $619,474 $619,474 100%
IPV (NVS) $3,447,100 $3,447,100 $1,619,537 47%
Measles (NVS) $430,138 $615,638 $381,619 89%
Measles-Rubella (NVS) $4,495,177 $4,495,177 $4,495,177 100%
Meningitis A - campaign (NVS) $2,670,736 $2,670,736 $2,670,736 100%
Meningitis A - operational costs (OPC) $2,567,107 $2,567,107 $2,567,107 100%
MR - Operational costs (OPC) $4,158,500 $4,158,500 $4,158,500 100%
Penta (NVS) $43,450,615 $45,049,115 $41,655,845 96%
Pneumo (NVS) $28,056,595 $33,404,595 $30,809,598 110%
Rotavirus (NVS) $6,577,104 $9,035,604 $6,214,385 94%
Vaccine Introduction Grant (VIG) $2,202,000 $2,202,000 $2,202,000 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Senegal DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2015)

Grade of confidence


N/A
DTP3 - Official country estimates (2015) 89%
M:F sex ratio at birth (2016) 1.04
Household survey: DTP3 coverage for male (2012) 88.90%
Household survey: DTP3 coverage for female (2012) 88.10%
Household survey: Last DTP3 survey (2012) 89%
% districts achieving > 80% DTP3 coverage (2015) 68%
% districts achieving < 50% DTP3 coverage (2015) 1%
MCV WHO/UNICEF estimates (2015) 80%

Breakdown of support

Non-vaccine support Vaccine support
18% 82%
$19,964,520 $88,640,210

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Senegal

27 July 2016

First Sudanese child to receive Meningitis A vaccine as part of routine immunization.

Sudan: first to introduce life-saving meningitis A vaccine into routine immunization

Children in Sudan are set to become the first in the Meningitis belt to benefit from the introduction of Meningitis A vaccine into a routine immunization programme.

26 February 2016

Gavi item

Positive impact of Advance Market Commitment highlighted in report

Innovative financing mechanism helping pneumococcal vaccines reach poorest children in record time.

22 February 2016

Gavi item

Meningitis A nearly eliminated in Africa through vaccination

Joint press release first published by WHO and PATH, joint founders of the Meningitis Vaccine Project.

close icon

modal window here